Superior anti-tumor activity of NC18, a novel HER2-targeting ADC, against enhertu-resistant CDX model

被引：0
|
作者：
Zhi, L. [1 ]
Sun, B. [1 ]
Kan, X. [1 ]
Ren, S. [1 ]
机构：
[1] Novacyte Therapeut Co Ltd, Dept Res & Dev, Beijing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.211
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
189P
引用
收藏
页码：S1477 / S1477
页数：1
相关论文
共 13 条
  • [1] A bispecific HER2 targeting FynomAb with superior anti-tumor activity and novel mode of action
    Schade, Babette
    Brack, Simon
    Attinger-Toller, Isabella
    Klupsch, Kristina
    Woods, Richard
    Hachemi, Helen
    von der Bey, Ulrike
    Kooenig-Friedrich, Susann
    Bertschinger, Julian
    Grabulovski, Dragan
    CANCER RESEARCH, 2014, 74 (19)
  • [2] HER2-targeting immunocytokine stimulated anti-tumor immune profile and marked efficacy in mouse tumor model
    Lan, K. H.
    Tsai, C. L.
    Kuo, S. H.
    Lan, K. L.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S69 - S69
  • [3] HER2 TKIs enhance the anti-tumor activity of HER2-targeting CAR-T and CAR-NK cells against NSCLC
    Yang, Yan
    Nilsson, Monique B.
    Poteete, Alissa
    He, Junqin
    Huang, Qian
    Heymach, John V.
    CANCER RESEARCH, 2024, 84 (06)
  • [4] BL-M07D1, a novel HER2-targeting ADC, demonstrates potent anti-tumor efficacy in preclinical pharmacodynamic models
    Wan, Weili
    Zhao, Shuwen
    Zhuo, Shi
    Zhang, Yong
    Chen, Lan
    Li, Gangrui
    Khalili, Jahan Salar
    Xiao, Sa
    Yan, Yongqi
    Shen, Xuejiao
    Zhu, Yi
    CANCER RESEARCH, 2023, 83 (07)
  • [5] HER2-targeting CAR-T cells show highly efficient anti-tumor activity against glioblastoma both in vitro and in vivo
    Li, Xueying
    Zhao, Lifen
    Li, Wenzhe
    Gao, Peng
    Zhang, Nianzhu
    GENES AND IMMUNITY, 2024, 25 (03) : 201 - 208
  • [6] DB-1303, a HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising safety profile and anti-tumor efficacy with differentiation from DS-8201a
    Lin, S.
    Zhang, Y.
    Li, B.
    Shi, R.
    Qiu, Y.
    Hua, H.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S91 - S91
  • [7] Superior anti-tumor activity compared to T-DM1 in preclinical studies of targeted therapies for her2-positive cancers by a novel her2-ADC ZV0201
    Zhang, Hong
    Li, Zhaohui
    Zhu, Tong
    Cao, Sheldon
    Chen, Gang
    Miao, David
    CANCER RESEARCH, 2015, 75
  • [8] Anti-tumor activity of a novel selenonucleoside via targeting Skp2 degradation in paclitaxel-resistant prostate cancer
    Byun, Woong Sub
    Jin, Minkyung
    Yu, Jinha
    Kim, Won Kyung
    Jeong, Lak Shin
    Lee, Sang Kook
    CANCER RESEARCH, 2019, 79 (13)
  • [9] ABC101-1, a novel microtubule inhibitor antibody-drug conjugate targeting HER2, has potent anti-tumor activity in a breast cancer model
    Kim, Seo Woo
    Yu, Hana
    Lee, Geon Ho
    Lim, Tae Gyu
    Jeong, Minji
    Hwang, Hyeonjoo
    Moon, Jee Eun
    Lee, Yong Beom
    Jin, Sung-Ha
    Jeong, Jin Hyun
    CANCER RESEARCH, 2024, 84 (03)
  • [10] HMA800067, a novel CD38-targeting antibody-drug conjugate (ADC), demonstrated superior anti-tumor activity to daratumumab in preclinical B-cell malignancies models
    Xu, Yan
    Liang, Junqing
    Jiang, Shuwen
    Yang, Haibin
    Zhang, Hui
    Mao, Fangfang
    Zhu, Jiahuan
    He, Jianlin
    Yang, Na
    Wang, Jian
    Zhang, WeiHan
    Ren, Yongxin
    Su, Weiguo
    CANCER RESEARCH, 2024, 84 (06)
12